Doug Kohrs Named to Sequana Medical Board of Directors

Very eexperimented WE medical technology chief brings over 40 years of experience

Ghent, Belgium19 Julily 2022 Sequana Medical SA (Euronext Brussels: SEQUA) (there “Company” Where “Sequana medicalI“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent non-executive director of the company. Mr. Kohrs is a highly experienced American executive with over 40 years of experience in the medical device industry.

“Doug Kohrs brings to our board considerable experience through his many roles as a founder and leader of leading medical technology companies,” said Pierre Chauvineau, Chairman of the Board of Sequana Medical. “Doug’s arrival is timely as we move towards the commercial launch of alphapump® in North America and our listing ambition in the United States. His extensive experience in building successful medical technology companies, with multiple financings and strategic transactions, will be invaluable as we continue to grow our business.

Mr Kohrs added: “I look forward to working with Sequana’s medical board and management team to successfully bring the alphapumps and DSR treatments to patients who need them. Drug-resistant fluid overload is a big challenge, especially in the United States where NASH is a growing problem and each year 200,000 heart failure patients are repeatedly hospitalized for fluid overload. Based on real patient experiences and clinical trial results, I believe Sequana Medical is well positioned to help these patients.

Mr. Kohrs is currently President and CEO of Responsive Arthroscopy, a company he founded that focuses on innovative surgical solutions for orthopedic surgery centers. In 2013, he also founded Responsive Orthopedics, a value-based medical device company, of which he served as CEO until its acquisition by Medtronic in June 2016. From 2006 to 2012, he was CEO and Chairman of Tornier NV, and from 1999 to 2005 he was CEO and President of American Medical Systems. Mr. Kohrs was also one of the founders of Spine Tech, a pioneering spine surgery company, where he worked in R&D and marketing roles from 1991 to 1998. Prior to that, he spent seven years at Johnson and Johnson Orthopedics as Chief Press Designer. Suitable for the knee condylar (PFC) and hip PFC systems.

Mr. Kohrs currently serves on the board of Cerapedics, Lima Orthopedics, Osteal Therapeutics, UroTronic and Vergent Bioscience. Mr. Kohrs previously served on the public company boards of ev3 (acquired by Covidien), Kyphon (acquired by Medtronic) and Protolabs, and the private company boards of Imascap (acquired by Wright Medical) , Pioneer Surgical (acquired by RTI Surgical), SpineCore (acquired by Stryker), and five other cards. Mr. Kohrs holds a BS in Bioengineering from Texas A&M University, a BA in Engineering Science from Austin College and an MBA from Northeastern University.

The appointment of Mr. Kohrs is subject to the approval of the Board of Directors and will also be subject to the approval of the Company’s next Shareholders’ Meeting. His appointment is effective as of today.

For more information please contact:

Sequana Medical

Optimal strategic communications

About Sequana Medical

Sequana Medical NV is a pioneer in the treatment of drug-resistant fluid overload, a serious and common clinical complication in patients with liver disease and heart failure. Fluid overload is a well-known problem in these growing diseases, causing serious problems for the large number of patients for whom current medications are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, leading to major medical issues including increased mortality, repeated hospitalizations, severe pain, labored breathing, and reduced mobility that severely affect daily life. .

alphapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to eliminate this excess fluid, delivering major clinical and quality of life benefits to patients and reducing costs to healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and is headquartered in Ghent, Belgium. For more information, please visit

Important Regulatory Disclaimers

The alphapump® is not currently approved in the United States or Canada. In the United States and Canada, the alphapump is currently under clinical investigation (POSEIDON study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information on the POSEIDON clinical study, see DSR® Therapy is still under development and it should be noted that any statements regarding safety and efficacy derive from ongoing preclinical and clinical studies which have not yet been completed. DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and the ongoing investigations with the alphapump system in Europe, the United States or Canada.

To note: alphapump® is a registered trademark. DSR® and alphapump DSR® are registered trademarks in Benelux, China, EU, UK and Hong Kong.

Forward-looking statements

This press release may contain predictions, estimates or other information that could be considered forward-looking statements. These forward-looking statements are not guarantees of future performance. These forward-looking statements represent Sequana Medical’s current judgment of what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to issue updates or revisions to the forward-looking statements contained in this press release, except as specifically required by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the views of Sequana Medical only as of the date of this press release.

  • Press release_US Board Nomination_July 19, 2022_NL_vF

  • Press release_US Board Nomination_July 19, 2022_FR_vF

Comments are closed.